Non-Invasively Diagnosed NASH/MASH and NAFLD/MASLD

If you have  NASH/MASH or NAFLD/MASLD, you may qualify for one of our research studies.

Qualified volunteers may receive at no cost:

• investigational medication
• study-related care from a local doctor
• possible compensation

Health insurance isn’t required to participate.
Ask your doctor or contact our clinic for more information.

Or sign up below and we will contact you!

Study Information below is from Clinicaltrials.gov

Inclusion Criteria:

Main Study Only:

• Males and non-pregnant, non-lactating females between 18 – 80 (between 19-80 in the Republic of Korea) years of age inclusive, on the day of signing informed consent

• Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes

• Suspected or confirmed diagnosis of NASH/MASH or NAFLD/MASLD or non-invasively diagnosed NASH/MASH or NAFLD/MASLD

Open-Label Rollover

• Prior participation in the placebo arm of a previous Akero Phase 2 study

Exclusion Criteria:

• Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results, including but not limited to: alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], autoimmune hepatitis), drug induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency

• Type 1 or unstable Type 2 diabetes

A reduced list of inclusion and exclusion criteria apply to participants in the open-label rollover extension.

Other inclusion and exclusion criteria may apply.

GSK 301160 ZENITH 1 MASH 

Purpose of the Study:

This study is testing efimosfermin alfa to see if it can safely reduce liver inflammation, improve liver scarring, and help prevent liver-related health problems in people with MASH and moderate to advanced liver fibrosis . MASH stands for Metabolic Dysfunction-Associated Steatohepatitis.

You may qualify if you:

• Are 18 to 75 years old.
• Have MASH (fatty liver disease with inflammation) confirmed by a liver biopsy.
• Have moderate to advanced liver scarring (F2 or F3 fibrosis).
• Have at least 2 features of metabolic syndrome, such as obesity, high blood pressure, high blood sugar, or abnormal cholesterol levels. 

You may not qualify if you:

• Cannot have a liver biopsy.
• Have severe liver disease, cirrhosis, or signs of liver failure.
• Have certain liver infections, including hepatitis B, hepatitis C, or HIV.
• Have significant kidney problems.
• Have poorly controlled diabetes.
• Regularly consume excessive amounts of alcohol.
• Have abnormal liver blood tests that suggest advanced liver disease

A study team member will review your medical history to determine if the study is right for you.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

GSK 306246 ZENITH 2 MASH (JAJ) 

You may qualify if you:

• Are 18 to 75 years old.
• Have known or suspected MASH (fatty liver disease with inflammation).
• Have evidence of moderate to advanced liver scarring (fibrosis F2 or F3).
• Have at least 2 features of metabolic syndrome, such as obesity, type 2 diabetes, high blood pressure, or abnormal cholesterol. [linkedin.com], [clinicaltrials.gov]

You may not qualify if you:

• Have severe liver disease or cirrhosis.
• Have hepatitis B, hepatitis C, HIV, or another chronic liver disease.
• Have poorly controlled diabetes (HbA1c 9% or higher).
• Have significant kidney disease.
• Have abnormal liver tests that suggest advanced liver damage.

A study team member will review your medical history to determine if the study is right for you.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.